Spots Global Cancer Trial Database for FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Official Title: A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
Study ID: NCT04245722
Study Description
Brief Summary: This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Chicago, Chicago, Illinois, United States
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
NYU Langone Health, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Sarah Cannon Research Institute (Tennessee Oncology), Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
SCRI-TTI, San Antonio, Texas, United States
Swedish Cancer Institute, Seattle, Washington, United States
Contact Details
Name: Fate Trial Disclosure
Affiliation: Fate Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
